DEBLURRING FLUORESCENCE MICROSCOPE IMAGES

描述：该项目的目标是开发改进的数字 活体和活体动物光学显微镜图像去模糊技术 用荧光抗体或指示染料标记的固定细胞。 这 将自动分析人类和哺乳动物的细胞图像 更快，更准确，从而提高了实用性 未来的临床诊断和研究工具。 同相 提议者将评估2-D和3-D图像去模糊的使用 自动荧光图像采集技术。 他们将 实现并测试了大量的图像去模糊技术， 单个输入图像和少量光学截面图像。 他们 将测试传统的线性滤波和非线性滤波 形态学处理和小波变换等技术 对二维图像进行过滤。 他们还将测试光学系统的去模糊功能， 截面图像的确定性和迭代方法，融合 对断层图像进行小波变换。 如果一个组合 这些技术被证明影响显著的图像质量 改进后，他们将在第二阶段项目中进行商业化。 其目的是将新技术纳入PSI的ProbeMaster 细胞遗传学自动化设备生产线。 拟定商业应用： 一旦新技术被开发出来，并有资格用于日常工作， 应用程序，他们将被纳入PSI的ProbeMaster产品 细胞遗传学自动化设备线，无论是在新的系统出售， 作为对细胞遗传学实验室中已经使用的现有系统的升级， 从而使该技术迅速商业化。

DESCRIPTION: The goal of this project is to develop improved digital image deblurring techniques for light microscope images of living and fixed cells labeled with fluorescent antibodies or indicator dyes. This will make the automated analysis of human and mammalian cell images significantly faster and more accurate, thereby enhancing the utility of future instruments in clinical diagnosis and in research. In Phase I the proposers will evaluate the use of 2-D and 3-D image deblurring techniques in automatic fluorescent image acquisition. They will implement and test a number of image deblurring techniques using both single input images and a small number of optical section images. They will test conventional linear filtering and nonlinear filtering techniques such as morphological processing and wavelet transform filtering on 2-D images. They will also test the deblurring of optical section images by deterministic and iterative methods, and the fusion of section images by wavelet transform methods. If one combination of these techniques proves to effect a significant image quality improvement, they will pursue commercialization in a Phase 2 project. The intent is to incorporate the new techniques into PSI's ProbeMaster product line of cytogenetics automation equipment. PROPOSED COMMERCIAL APPLICATION: As soon as the new techniques are developed and qualified for routine application, they will be incorporated into PSI's ProbeMaster product line of cytogenetics automation equipment, both in new systems sold and as an upgrade to existing systems already in use in cytogenetics labs, thus commercializing the technology quickly.